Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Solid Tumor 1Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × LY2510924 × Clear all
NCT02652871 2019-11-15

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
36 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
9 enrolled 13 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡